FEATURED NEWS

• HDA Statement on 2020 Presidential Election

  November 8, 2020

  Healthcare Distribution Alliance (HDA) President and CEO Chester “Chip” Davis, Jr., released the following statement.

• HDA Research Foundation Survey Depicts Supply Chain's DSCSA Implementation Progress

  November 2, 2020

  A survey released today by the Healthcare Distribution Alliance (HDA) Research Foundation indicates the pharmaceutical supply chain continues to make steady progress to comply with the 2013 Drug Supply Chain Security Act (DSCSA); however, some implementation priorities have shifted amid the initial industry response to the COVID-19 pandemic.

• HDA Statement on Proposed DEA Rule on Suspicious Orders

  November 2, 2020

  Healthcare Distribution Alliance (HDA) President and CEO Chester “Chip” Davis, Jr., released the following statement regarding the Drug Enforcement Administration’s (DEA) proposed rule on suspicious orders.

• US Biopharmaceutical Supply Chain Resilient and Effective During Early COVID-19 Response

  October 26, 2020

  A report published by the Healthcare Distribution Alliance (HDA) Research Foundation and Deloitte Consulting LLP found that during the first 90 days of the COVID-19 pandemic, the biopharmaceutical finished goods industry quickly adapted and adjusted to deliver medicines safely and efficiently to patients, with only minimal disruptions.

• HDA Statement on FDA’s Drug Supply Chain Security Act-Related Enforcement Discretion

  October 22, 2020

  In response to the Food and Drug Administration’s (FDA) decision to extend enforcement discretion related to certain Drug Supply Chain Security Act requirements, the Healthcare Distribution Alliance (HDA) released the following statement.